What's on the label is the measured result — net peptide mass, not gross powder weight, plus RP-HPLC purity, on a lot-numbered COA for every batch.
Net peptide mass and RP-HPLC purity — a lot-numbered COA for every batch.
Net peptide mass + HPLC purity, per lot.
PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epitalon. Read our briefing →
PCAC will review 7 peptides for the 503A bulks list. Read →
FDA PCAC reviews 7 peptides in July. Read →
GLP-1 / glucagon dual receptor agonist (BI 456906)
PeptideXpo primary owner
This PeptideXpo page is the primary SEO owner for buyers evaluating Survodutide through broad supplier qualification, distributor assortment planning, OEM catalog coverage, and repeat-order economics. It should help the buyer decide whether this SKU belongs in a larger peptide sourcing program before specialist analytical or pharmacy documentation review.
Overview
Survodutide (development code BI 456906) is an investigational dual GLP-1 / glucagon receptor co-agonist developed by Boehringer Ingelheim and Zealand Pharma, currently in Phase 3 development for chronic weight management and metabolic-disease-associated liver indications including MASH (metabolic-associated steatohepatitis). Like Mazdutide, Survodutide engages only the GLP-1 and glucagon receptor arms, distinct from the GIP-containing dual / tri-agonist class, positioning the molecule as a research tool for glucagon-pathway pharmacology and as a clinical-development asset for indications where glucagon-mediated hepatic-energy-expenditure effects are therapeutically valuable. PeptideXpo supplies Survodutide acetate as a lyophilized powder at ≥99.0% HPLC purity. The 10 mg standard fill size covers typical research aliquot work. The analytical packet emphasizes confirmation of identity by mass spec because Survodutide's structure is similar enough to other GLP-1 / glucagon dual agonists that cross-supplier confusion is possible at the catalog-listing level, sequence verification by LC-MS/MS on first-time orders is recommended.
Who buys this, and why
Most buyers in this category are 503A and 503B compounding pharmacies fulfilling metabolic and weight-management protocols, plus research labs investigating GLP-1 / GIP / GCG receptor pharmacology. The procurement decision usually hinges on three things: documented purity at scale, a regulatory team that can respond on destination-market questions in writing, and the ability to supply consistent counter-ion form (acetate by default) across recurring orders.
Primary buyer fit: academic and contract research laboratories.
Specifications
Documentation available on request
Regulatory note
Investigational compound in Phase 3 development (Boehringer Ingelheim / Zealand Pharma); not approved as a finished drug. Supplied for research use only. CAS commonly cited but should be verified per batch COA.
Frequently asked questions
Both are dual GLP-1 / glucagon receptor co-agonists in Phase 3 development, with no GIP component, distinguishing them mechanistically from Tirzepatide (GIP+GLP-1) and Retatrutide (GIP+GLP-1+glucagon). The two molecules differ in their specific peptide sequences and lipidation chemistry, but at the receptor-pharmacology level they are mechanistically similar. The clinical-development indication mix differs: Mazdutide is primarily targeting chronic weight management and type 2 diabetes through Innovent / Eli Lilly's China-focused program, while Survodutide is targeting both weight management and metabolic-liver indications (MASH) through Boehringer Ingelheim / Zealand Pharma. Buyers should verify exact identity per batch COA before treating the two as interchangeable in research contexts.
The glucagon receptor agonist arm of dual GLP-1/glucagon co-agonists like Survodutide produces direct hepatic-energy-expenditure effects, which translate to reduced hepatic steatosis (fat accumulation in the liver) and reduced hepatic inflammation in metabolic-liver models. MASH is the inflammatory progression of NAFLD characterized by both steatosis and inflammation, and addressing both pathways requires a mechanism that goes beyond the incretin-axis-only effects of GIP/GLP-1 agonists like Tirzepatide. Survodutide's Phase 2 MASH data (the LIVE-1 study, published 2024) supported the Phase 3 program expansion into the MASH indication alongside the more conventional weight-management endpoints, making Survodutide a useful research tool for buyers studying both metabolic and hepatic endpoints in the same model.
Survodutide originated from Zealand Pharma's peptide-engineering platform, which has produced multiple commercially relevant peptides including the cancer-associated obesity drug Bachem-partnered Glepaglutide. The molecule was out-licensed to Boehringer Ingelheim, who is leading the global Phase 3 development program. This origin distinguishes Survodutide commercially from Mazdutide (Innovent/Lilly partnership, China-focused) and from Tirzepatide / Retatrutide (Lilly internal pipeline). For research procurement, the development-partner identity doesn't affect the bulk material PeptideXpo supplies, what matters operationally is matching the specific molecule to the clinical-data reference relevant to your work.
Related peptides
